-
Mashup Score: 10
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value enter ed is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. This value is admissible, but you may wish to double check it. This field must be a 5 or 9 digit U.S. ZIP Code (like 94043). Please re-enter it now. This field must be a 10 digit U.S. phone number (like 415 555 1212). Please re-enter it now. This
Source: redcap.iths.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 18
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and remains a major therapeutic challenge. There is substantial variability across transplantation and cellular therapy programs in assessing and managing post CAR-T failures in RRMM. The American Society for Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines conducted an online cross-sectional survey between September 2023 and December 2023 to determine the myeloma, transplantation and cellular therapy physicians’ practice patterns for surveillance, diagnosis, and management of CAR-T failure.
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1FDA’s ODAC Rules Unanimously on a Faster Way to Approve Multiple Myeloma Therapies - Florida Hospital News and Healthcare Report - 27 day(s) ago
“Today’s unanimous ODAC vote – 12-0 in favor – is a milestone for the field of multiple myeloma,” said Dr. C. Ola Landgren, director of Sylvester’s Myeloma Research Institute. “It […]
Source: southfloridahospitalnews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Sleep disturbance in cancer patients referred to an ambulatory integrative oncology consultation - PubMed - 28 day(s) ago
Although 64% of patients seeking IO consultation reported clinically significant SD, only 11% were seeking integrative approaches for managing SD. ESAS fatigue, hot flashes, well-being, and psychological symptoms were significantly associated with SD.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1XII International Conference “Complex treatment of plasma cell dyscrasias in 2024” - WELCOME ADDRESS - 28 day(s) ago
By using this website, you consent to us using cookies as described in this policy
Source: szpiczak2024.jordan.plCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4
Blood Cancer Journal – Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake - 1 month(s) ago
About 15 years ago, Carl Ola Landgren, M.D. Ph.D., noticed an encouraging yet potentially concerning trend in the treatment of multiple myeloma. | At an FDA advisory committee meeting this Friday, two teams will present their studies examining the utility of minimal residue disease (MRD) as a potentially approvable endpoint in multiple myeloma. For this report, Fierce Pharma spoke with experts to learn about what’s at stake, including the need to bring new treatments to patients earlier.
Source: www.fiercepharma.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling - 1 month(s) ago
Traditional prognostic models for newly diagnosed patients with multiple myeloma (MM), including International Staging System criteria and number of high-risk chromosomal abnormalities, are based on disease characteristics at diagnosis. However, the identification of patients at risk of more rapidly progressive MM is inherently a dynamic assessment. In a subset of patients with MM, adverse disease biology only becomes evident after the failure of first-line therapy. We define this entity as functional high-risk MM (FHRMM), encompassing relapse within 18 months of treatment initiation and/or within 12 months of frontline autologous stem cell transplantation. FHRMM is not adequately captured by traditional prognostic models, and there is a need for better understanding of mechanisms or risk factors for early relapse or progression. In this review, we explore potential definitions of FHRMM before delving into its underlying drivers based on genetic, transcriptomic, and immune cell profili
Source: www.frontiersin.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary - 1 month(s) ago
Chimeric antigen receptor-modified T cell (CAR-T) therapy has become a critical part of the armamentarium for the treatment of relapsed/refractory hematologic malignancies. As our experience with CAR-T therapy grows and new data emerge, the identification of suitable patients has become more complex. The Community Oncologist Patient ID Roundtable, held on May 16, 2023, brought together 3 professional societies— (American Society for Transplantation and Cellular Therapy [ASTCT], Association of Community Cancer Centers [ACCC], and Association of American Cancer Institutes [AACI])—with the aim of developing a standardized framework to enable community oncology care teams to assess patients more easily for CAR T consultation, with a focus on large B cell lymphoma (LBCL).
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Frontiers | Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma - 1 month(s) ago
Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated…
Source: www.frontiersin.orgCategories: General Medicine News, Hem/OncsTweet-
@drjgauthier @AJPortuguese @fredhutch @UWMedicine Thank you Jordan! Indeed, this was the case report most similar to our case. Potentially, in some, more α4β7 expression on certain CAR T-cells (and/or auto-reactive retained TCR) mean more gut trafficking and thus colitis? Looks like GVHD, but not! https://t.co/YCws9gP2KH
-
@BloodCancerJnl And here's the first image again, in case it's not loading - thank you all in advance for your help with this #MMsm survey! https://t.co/EjLgfRgG2Z https://t.co/FE23ABuG1r